1. Dual-Action Protein-siRNA Conjugates for Targeted Disruption of CD47-Signal Regulatory Protein α Axis in Cancer Therapy.
- Author
-
Lee JW, Yoon HY, Ko YJ, Kim EH, Song S, Hue S, Gupta N, Malin D, Kim J, Kong B, Kim S, Kim IS, Kwon IC, Yang Y, and Kim SH
- Subjects
- Humans, Animals, Mice, Neoplasms therapy, Neoplasms genetics, Neoplasms pathology, Antigens, Differentiation, Cell Line, Tumor, CD47 Antigen metabolism, CD47 Antigen chemistry, RNA, Small Interfering chemistry, Receptors, Immunologic metabolism
- Abstract
A series of successes in RNA interference (RNAi) therapies for liver diseases using lipid nanoparticles and N -acetylgalactosamine have heralded a current era of RNA therapeutics. However, alternative delivery strategies are required to take RNAi out of the comfort zone of hepatocytes. Here we report SIRPα IgV/anti-CD47 siRNA (vS-siCD47) conjugates that selectively and persistently disrupt the antiphagocytic CD47/SIRPα axis in solid tumors. Conjugation of the SIRPα IgV domain protein to siRNAs enables tumor dash through CD47-mediated erythrocyte piggyback, primarily blocking the physical interaction between CD47 on cancer cells and SIRPα on phagocytes. After internalization of the vS-siCD47 conjugates within cancer cells, the detached free-standing anti-CD47 siRNAs subsequently attack CD47 through the RNAi mechanism. The dual-action approach of the vS-siCD47 conjugate effectively overcomes the "don't eat me" barrier and stimulates phagocyte-mediated tumor destruction, demonstrating a highly selective and potent CD47-blocking immunotherapy. This delivery strategy, employing IgV domain protein-siRNA conjugates with a dual mode of target suppression, holds promise for expanding RNAi applications beyond hepatocytes and advancing RNAi-based cancer immunotherapies for solid tumors.
- Published
- 2024
- Full Text
- View/download PDF